Search Videos and More
Course
Cannabis and Oncology Care: How to Guide Adults with Cancer
Learn evidence-based cannabis therapeutics for oncology patients — including clinical indications, risk assessment, and conversation frameworks-grounded in ASCO's 2024 clinical guideline for adults with cancer.
Podcast
Season 3, Episode 1: Advances in Endometrial Cancer Research
Cigall Kadoch had a hunch that the research in her lab might be relevant to endometrial cancer research. She had spent more than a decade studying the molecular machinery that unwinds DNA in the nucleus of a cell to make the right DNA instructions readable by the cell at the right time.
News
Rare Inherited EGFR Mutation Linked to Dramatically Increased Lung Cancer Risk
A rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute. The findings included de-identified, aggregated genetic data from more than 3.3 million 23andMe research-consented participants.
News
Building a System of Focused Care for Lobular Breast Cancer
How Dana-Farber investigators are pioneering new approaches to help understand, diagnose, and treat this distinct form of breast cancer
News
Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027
U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.
News
Dana-Farber Research News 09.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 16 - 31.
News
Dana-Farber Science Backs Development of Targeted Therapy for Rare GIST Cancer
Some things are best kept under lock and key, like oncogenes, which are genes that are associated with cancer growth because they signal cells to grow rapidly.
News
Targeting CDK2 Could Boost Immunotherapy Response in Patients With a Wide Range of Cancers, According to Dana-Farber Science
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could potentially be more broadly applicable to a wide range of cancers when combined with immunotherapy.
News
Dana-Farber Research News 09.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 1 - 15.
News
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber
he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Course
Stem Cell Transplant and Cellular Therapies Symposium 2026:
Navigating a Rapidly Changing Landscape
News
Dana-Farber Research News 08.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 16 - 31.